Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3171/2014.5.JNS141078 | DOI Listing |
Urology
November 2023
Emory University Department of Urology, Emory University School of Medicine, Atlanta, GA; Department of Urology, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA.
Congenital melanocytic nevi are present at birth or develop within the first few months of life. Giant congenital melanocytic nevi are a rare variant and may involve the external genitalia with a confluent "bathing trunk" distribution. Rapid growth of proliferative nodules of melanocytic cells may cause disfigurement and anatomical distortion resulting in psychological distress and loss of functionality.
View Article and Find Full Text PDFJ Pediatr Urol
October 2023
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Background: Management patterns and outcomes are poorly defined in cases of late PUV diagnosis.
Objective: To compare post-ablation management and clinical outcomes of patients with infantile (<1 year) versus childhood (>5 year) PUV diagnosis to gain insight into the pathologies at opposite ends of the PUV spectrum.
Study Design: A multicenter retrospective cohort study was conducted using the TriNetX research network between 2006 and 2022.
Urology
November 2023
Pediatric Urology Department, Emory University School of Medicine, Sandy Springs, GA; Pediatric Urology Department, Children's Healthcare of Atlanta, Atlanta, GA. Electronic address:
Rhabdomyosarcoma (RMS) treatment involves surgery, chemotherapy, and radiotherapy. A radioprotective space between the bladder/prostate and rectum reduces postradiation complications, as reported in adult patients. Describe pediatric preradiotherapy perirectal hyaluronic acid (HA) spacer injection for bladder/prostate RMS.
View Article and Find Full Text PDFArthritis Rheumatol
September 2023
UCL Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College London Medical School, London, UK.
Objective: This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc).
Methods: A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST).
Results: The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.
J Pediatr Urol
August 2023
Division of Pediatric Urology, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!